

Initiator Pharma updates the timeline for the rights issue

Initiator Pharma updates the timeline for the rights issue, the record date is on June 10, 2025 and the subscription period runs from and including June 12, 2025 up to and including June 26, 2025.

On May 19, 2025, Initiator Pharma announced that the company has resolved on a rights issue of SEK 56 million. As Initiator Pharma is a Danish company with shares issued in Denmark but admitted to trading at Nasdaq First North Growth Market in Stockholm, the rights issue needs to accommodate routines set by both Euroclear in Sweden and Euronext Securities Copenhagen (VP Securities). Hence, the timeline for the rights issue is updated according to the following:

Last day of trading in shares including subscription rights 5 June 2025

First day of trading in shares excluding subscription rights 9 June 2025

Estimated publication of the Information Memorandum 10 June 2025

Record date in the Rights Issue 10 June 2025

Subscription period 12 – 26 June 2025

Trading in subscription rights 12 – 23 June 2025

Trading in paid subscribed shares (BTA) 12 – 1 July 2025

Expected announcement of the preliminary outcome in the Rights Issue 1 July 2025

For additional information about Initiator Pharma, please contact:

Claus Elsborg Olesen, CEO
Telephone: +45 6126 0035
E-mail: ceo@initiatorpharma.com

About Initiator Pharma

Initiator Pharma A/S is a Danish clinical stage emerging pharma company developing innovative drugs that target key unmet medical needs within the central and peripheral nervous system. Initiator Pharma's pipeline consists of two clinical stage assets – pudafensine and IP2018 – and two preclinical assets. With pudafensine the company has reported positive, statistically significant and clinically relevant efficacy data in a Phase IIb clinical trial with patients suffering from ED. With IP2018 the company has reported positive, statistically significant, and dose-dependent clinical observations related to efficacy in psychogenic erectile dysfunction (ED) in a Phase IIa clinical trial of IP2018 in patients with mild to moderate ED.

Initiator Pharma is listed on Nasdaq First North Growth Market (ticker: INIT). Redeye AB is the company's Certified Adviser. For more information, please visit www.initiatorpharma.com.

Attachments

Initiator Pharma updates the timeline for the rights issue